US Races to Secure Biotech Edge as China Accelerates AI Integration
WASHINGTON – The United States is facing a critical juncture in its global technological leadership, as it lags behind China in integrating artificial intelligence with biotechnology. While Washington has prioritized AI investment, a lack of coordination and infrastructure threatens to cede ground in a field poised to define economic and national power in the coming decades, according to a recent analysis.
The convergence of AI and biotechnology isn’t simply about faster drug discovery; it’s about reshaping industries from agriculture and manufacturing to national defense. The ability to analyze and utilize vast biological datasets – DNA, RNA, proteins, and metabolites – is becoming a new form of strategic power, analogous to control over advanced semiconductors.
“Without large, representative, and interoperable biological datasets, AI models cannot generalize, scale, or translate into real-world impact,” the analysis states. The country that masters this intersection will dictate the pace of innovation across multiple sectors.
China’s Coordinated Approach
Beijing is pursuing a national strategy that explicitly links biotechnology, big data, and artificial intelligence, streamlining data generation, computing resources, and industrial application. This coordinated effort is exemplified by China’s rapidly growing non-invasive prenatal testing market, valued at roughly $608 million in 2023 and projected to exceed $1 billion by the end of the decade. Companies like BGI Group operate large-scale sequencing platforms, generating substantial genomic data within an integrated ecosystem.
China is also building the data infrastructure to support this integration, including the China National GeneBank DataBase, a centralized portal for biological big-data archival, sharing, and analysis. This system reduces friction between discovery and application, bolstering capabilities in areas like biodefense and supply chain resilience.
US Challenges: Fragmentation and Lack of Interoperability
The US, while possessing world-class public biodata repositories like the National Library of Medicine’s National Center for Biotechnology Information, suffers from fragmentation. These repositories were designed for open scientific access rather than coordinated industrial translation or AI optimization. Governance, interoperability, and commercialization pathways remain dispersed across agencies, universities, and private companies.
Specifically, the analysis points to four key challenges: a lack of data diversity – many datasets disproportionately represent individuals of European ancestry; inconsistent data quality; limited interoperability between datasets; and vulnerabilities in data security. Existing data is often not “AI-ready,” lacking the standardized formats and metadata needed for effective model training.
Recent US Efforts Fall Short
The recently released National Security Strategy and the National Defense Authorization Act acknowledge the importance of biotechnology, but the analysis argues that acknowledgements and pilot programs are insufficient. The Genesis Mission executive order, aimed at accelerating science through AI, risks exacerbating fragmentation without a coordinated effort to generate AI-ready biodata.
A Path Forward
Experts recommend treating biodata as critical national infrastructure, requiring significant public investment. The Department of Energy, in coordination with other agencies, should fund the commissioning of large, longitudinal datasets with standardized metadata and security classifications.
A secure national compute-to-data portal, allowing vetted users to access sensitive datasets through privacy-preserving machine learning, is also crucial. Furthermore, existing National Defense Authorization Act pilots should be converted into binding national standards for interoperability, auditability, and security.
“Losing this race is a choice, and the window to reverse course is closing,” the analysis concludes. “America can still lead. But leadership requires building, now, the biodata and related infrastructure that will define the biotech century.”
Michelle Holko, PhD, PMP, strategic innovator and former White House Presidential Innovation Fellow, and John Wilbanks, a researcher and entrepreneur focused on data accessibility, co-authored the analysis, alongside Sam Howell, an Associate Fellow with the Technology and National Security Program at the Center for a New American Security.
